GLS and cancer: In line with this, it was shown that cancer cells with KEAP1 mutation and/or NRF2 hyperactivation exhibit increased glutamine dependency and enhanced sensitivity to glutamine deprivation or glutaminase inhibition, partly via high SLC7A11-mediated glutamate export in these cancer cells (Romero et al., 2017; Sayin et al., 2017).